It has been shown that JNK inhibitors exerted their therapeutic effect in tumor through regulating the downstream effectors, such as c-Myc [29, 30], and that c-MYC plays a critical role in the proliferation of Ph+ B-ALL cells [32]. The gene discussed is MAPK8; the disease is acute lymphoblastic leukemia.